Impact of the Concomitant Use of Immunomodulator and a Lower Week 8 Partial Mayo Score on the Persistence of Adalimumab in Refractory Ulcerative Colitis

OBJECTIVE: Real-world data of adalimumab (ADA) in the treatment of ulcerative colitis (UC) are scarce. We aimed to study the ADA response rates and predictors of response in UC treatment. METHODS: This observational, prospective and multi-center study assessed the clinical outcome of refractory UC p...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumei, Shinsuke, Sakurai, Toshihiro, So, Suketo, Itaba, Soichi, Akiho, Hirotada, Nakamura, Shigeo, Kim, Hyonji, Yamasaki, Masahiro, Takatsu, Noritaka, Maekawa, Ryuichiro, Sakemi, Ryosuke, Watanabe, Tatsuyuki, Shibata, Michihiko, Kume, Keiichiro, Yoshikawa, Ichiro, Takaki, Yasuhiro, Harada, Masaru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758447/
https://www.ncbi.nlm.nih.gov/pubmed/34121007
http://dx.doi.org/10.2169/internalmedicine.7279-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8758447/
https://www.ncbi.nlm.nih.gov/pubmed/34121007
http://dx.doi.org/10.2169/internalmedicine.7279-21

Ejemplares similares